Retrospective observational study of salvage chemotherapy following nivolumab therapy in advanced non-small cell lung cancer

Retrospective observational study of salvage chemotherapy following nivolumab therapy in advanced non-small cell lung cancer - Retrospective exploratory study of salvage chemotherapy for nivolumab-refractory lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032667

Enrollment

Registered

2018-06-01

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Ww enroll the patients with relapsed or advanced non-small cell lung cancer who underwent salvage chemotherapy following progression after conventional cytotoxic chemotherapy and the subsequent nivolumab therapy.

Exclusion criteria

Exclusion criteria: The patients are excluded from the analysis if they had another neoplasm for the need of treatment, and if they received the preceding therapy of EGFR or ALK throsine kinase inhibitors before or after nivolumab therapy.

Design outcomes

Primary

Measure	Time frame
The primary endpoint is overall response of salvage chemotherapy in association with the characteristics of tumor-infiltrating immune cells.	—

Secondary

Measure	Time frame
The secondary endpoint is progression-free survival of salvage chemotherapy,	—

Countries

Japan

Contacts

Public ContactHiroshi Soda

Sasebo City General Hospital Department of Respiratory Medicine

h-souda@hospital.sasebo.nagasaki.jp0956-24-1515

Outcome results